A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : TRAb / TSH receptor antibody

[Related PubMed/MEDLINE]
Total Number of Papers: 276
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   TRAb  (>> Co-occurring Abbreviation)
Long Form:   TSH receptor antibody
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2023 Incidence of and Risk Factors for Neonatal Hypothyroidism among Women with Graves' Disease Treated with Antithyroid Drugs until Delivery. ATD, GD, MMI, PTU
2022 2021 Asia-Pacific Graves' Disease Consortium Survey of Clinical Practice Patterns in the Management of Graves' Disease. APAC, ATD, CBZ, GD, GO, MMI, PTU, RAI, TSH
2022 Applicability of polygenic risk scores in endometriosis clinical presentation. PRS
2022 Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves' disease: a systematic scoping review. ATD, GD
2022 Asymmetrical Graves' disease in children: potential usefulness of potassium iodide monotherapy. GD, TSH
2022 Changes in Glucose Intolerance after Treatment with Antithyroid Drugs in Patients with Graves' Disease Using Continuous Glucose Monitoring: A Pilot Study. 1,5-AG, CGM, CV, GD, MAGE, SD
2022 Clinical evaluation of an automated TSI bridge immunoassay in the diagnosis of Graves' disease and its relationship to the degree of hyperthyroidism. GD, ROC, TSH, TSI
2022 Different Characteristics of Orbital Soft Tissue Expansion in Graves Orbitopathy: Extraocular Muscle Expansion is Correlated to Disease Activity While Fat Tissue Volume With Duration. BV, BV, FV, GO, MV
2022 How to manage Graves' disease in women of childbearing potential. ATDs, GD, RAI
10  2022 Hyperthyroidism Presenting with Coronary Vasospasm. ---
11  2022 Mathematical Modeling of Free Thyroxine Concentrations During Methimazole Treatment for Graves' Disease: Development and Validation of a Computer-Aided Thyroid Treatment Method. CATT, DigiThy, GD, MMI, TSH
12  2022 MiR-29a-3p negatively regulates circulating Tfh memory cells in patients with Graves' disease by targeting ICOS. GD, ICOS, miRNAs, PBMCs
13  2022 Novel Insight into Non-Genetic Risk Factors of Graves' Orbitopathy. GD, GO, TgAb
14  2022 The Differential Effects of Propylthiouracil and Methimazole as Graves' Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial. CIMT, FT4, ICAM-1, PTU, PWV, TSH, VCAM-1
15  2022 The prevalence and significance of nonuniform thyroid radio-isotope uptake in patients with Graves' disease. ATD, GD
16  2022 Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy. CAS, GO, RTX
17  2022 TSH receptor antibodies (TRAb) - A potential new biomarker for endometriosis. FSH, FSHR, hCG, LH, LHR, TSH
18  2021 Alemtuzumab-induced autoimmune thyroid events in patients with relapsing-remitting multiple sclerosis: A real-life and monocentric experience at a tertiary-level centre. AIATEs, GD, RRMS
19  2021 Efficacy of low-dose methimazole in control of multiple relapses of Graves' hyperthyroidism: a case report. MMI
20  2021 Evaluation of the application of TSH receptor stimulating autoantibodies and the optimization of detection strategy in Graves' disease. AUC, TSI
21  2021 Graves' Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review). ATD, GD, ICPIs
22  2021 Intravenous rituximab therapy for active Graves' ophthalmopathy: a meta-analysis. CAS, GO, RTX, SMD
23  2021 Investigation of TSH receptor blocking antibodies in childhood-onset atrophic autoimmune thyroiditis. AAT, TSBAb
24  2021 Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study. COVID-19, SARS-CoV-2, TgAb, TPOAb
25  2021 Predicting the Course of Graves' Orbitopathy Using Serially Measured TSH-Receptor Autoantibodies by Automated Binding Immunoassays and the Functional Bioassay. GO, ROC
26  2021 Predicting the Relapse of Hyperthyroidism in Treated Graves' Disease with Orbitopathy by Serial Measurements of TSH-Receptor Autoantibodies. ATD, GD, GO
27  2021 Rapid Differential Diagnosis of Thyrotoxicosis Using T3/T4 Ratio, FT3/FT4 Ratio and Color Doppler of Thyroid Gland. DT, GD
28  2021 Role of the mononuclear cell infiltrate in Graves' orbitopathy (GO): results of a large cohort study. CAS, GO
29  2021 Serum thyroglobulin is associated with orbitopathy in Graves' disease. GD, GO, TPOAb, TgAb
30  2021 Targeted Temperature Management for In-hospital Cardiac Arrest Caused by Thyroid Storm: A Case Report. IHCA, ROSC, SCA, TSH, TTM, VF, VT
31  2021 The Relationship between Third-generation TSH Receptor Antibody Positivity and Cumulative Methimazole Dose Used until Remission in Graves' Disease. ---
32  2021 Third generation radioimmunoassay (RIA) for TSH receptor autoantibodies (TRAb) - one step less, similar results? AUC, GD, GDt, HD, HS, NAITD, RIA
33  2021 Thyrotropin receptor antibody immunoassays may not be reliable in confirming diagnosis of Painless Thyroiditis. GD, PT, TCTU
34  2021 [Graves' Disease]. AIT, GD, ICI
35  2020 Auto regulatory capacity of the thyroid gland after numerous iodinated contrast media investigations. FT4, IC, TPOAb, TSH
36  2020 fT3:fT4 ratio in Graves' disease - correlation with TRAb level, goiter size and age of onset. GD
37  2020 Long-term outcomes of graves disease in children treated with anti-thyroid drugs. ATD, GD
38  2020 Pitfalls in the assessment of gestational transient thyrotoxicosis. GD, GTT, hCG, TSH
39  2020 The association of TSH-receptor antibody with the clinical and laboratory parameters in patients with newly diagnosed Graves' hyperthyroidism: experience from a tertiary referral center including a large number of patients with TSH-receptor antibody-negative patients with Graves' hyperthyroidism. GD
40  2020 Use of Adjunctive Therapy to Achieve Preoperative Euthyroidism in Graves' Disease: A Case Report. FT4, TSH
41  2019 A case of Graves' disease developing with exacerbation of sarcoidosis. ---
42  2019 A novel third-generation TSH receptor antibody (TRAb) enzyme-linked immunosorbent assay based on a murine monoclonal TSH receptor-binding antibody. AUC, ELISAs, GD, HT, mAb, ROC, TSHR
43  2019 Active Moderate-to-Severe Graves' Orbitopathy in a Patient With Type 2 Diabetes Mellitus and Vascular Complications. DM, GD, GO
44  2019 Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy. ATD, CI, GD, HR, TgAb, TPOAb
45  2019 Graves' Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature. ICPIs, irAEs
46  2019 Graves' hyperthyroidism in pregnancy. ATD, MMZ, PTU
47  2019 High Thyroid Stimulating Receptor Antibody Titre and Large Goitre Size at First-Time Radioactive Iodine Treatment are Associated with Treatment Failure in Graves' Disease. GD, RAI, TSH
48  2019 Hyperthyroidism and hypopituitarism: two incompatible diagnoses? ---
49  2019 Liver enzyme profile and progression in association with thyroid autoimmunity in Graves' disease. ALP, AST, GD, GGT
50  2019 Predictors of Initial and Sustained Remission in Patients Treated with Antithyroid Drugs for Graves' Hyperthyroidism: The RISG Study. ATD, GH
51  2019 Role of a new bioassay for thyroid-stimulating antibodies (aequorin TSAb) in Graves' ophthalmopathy. cAMP, CAS, GO, TSAb
52  2019 The Effect of Radioiodine Treatment on TRAb, Anti-TPO, and Anti-TG in Graves' Disease. anti-Tg, anti-TPO, GD
53  2019 Thyroid vascularization is an important ultrasonographic parameter in untreated Graves' disease patients. ---
54  2019 [Update Graves' disease 2019]. AIT, GD, PTU
55  2018 Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features. ATDs, GD, MS, RAI, TD
56  2018 Characteristics of endometriosis: A case-cohort study showing elevated IgG titers against the TSH receptor (TRAb) and mental comorbidity. CI, OR, TPO, VAS-IBS
57  2018 Clinical diagnosis of Graves' or non-Graves' hyperthyroidism compared to TSH receptor antibody test. GD
58  2018 False-positive TSH receptor antibody-a pitfall of third-generation TSH receptor antibody measurements in neonates. GD
59  2018 Fetal hyperthyroidism associated with maternal thyroid autoantibodies: A case report. TSH
60  2018 General hyperpigmentation induced by Grave's disease: A case report. ACTH, TSH
61  2018 Graves' disease in clinical perspective. GD
62  2018 Hypothyroidism conversion to hyperthyroidism: it's never too late. TPO
63  2018 Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves' orbitopathy: a case series. MS, TED
64  2018 Laboratory Testing in Thyroid Conditions - Pitfalls and Clinical Utility. MTC, Tg, TgAb, TPOAb, TSH
65  2018 Management of fetal goiters: 6-year retrospective observational study in three prenatal diagnosis and treatment centers of the Pays De Loire Perinatal Network. FBS
66  2018 Morphea and antithyroid antibodies. TgAb, TSH
67  2018 The Relation Between Epicardial Fat Tissue Thickness and TSH Receptor Antibody in Hyperthyroidism. EFT
68  2018 Thyroid-associated orbitopathy in patients with thyroid carcinoma: A case report of 5 cases. GCs, TAO
69  2018 Thyrotrophin receptor antibody concentration and activity, several years after treatment for Graves' disease. TSAb
70  2018 TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy. BMD, GO
71  2018 Utility of systematic TSHR gene testing in adults with hyperthyroidism lacking overt autoimmunity and diffuse uptake on thyroid scintigraphy. TSHR
72  2017 A case of metastatic follicular thyroid carcinoma complicated with Graves' disease after total thyroidectomy. RAI
73  2017 Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy. GD, GO, IgG, IgG4
74  2017 Measuring TSH receptor antibody to influence treatment choices in Graves' disease. ATD, GD, GO, RAI
75  2016 Adjuvant Treatment of Graves' Disease with Diclofenac: Safety, Effects on Ophthalmopathy and Antibody Concentrations. COX-2, GD, GO, PPARgamma
76  2016 Changes in bone mineral density and trabecular bone score in Graves' disease patients after anti-thyroid therapy. BMD, IQR, TBS, TSH
77  2016 Effect of Selenium Supplementation on Recurrent Hyperthyroidism Caused by Graves' Disease: A Prospective Pilot Study. MMI, TSH
79  2016 Graves Disease Induced by Radioiodine Therapy for Toxic Nodular Goiter: A Case Report. GD, MNG, RAIT, TA
80  2016 High levels of DNA polymerase beta mRNA corresponding with the high activity in Graves' thyroid tissue. DNA poly beta, TSH
81  2016 High prevalence of anti-TSH receptor antibody in fibromyalgia syndrome. AITD, FMS, TgAb, TPOAb, TSH
82  2016 Partial prediction of postpartum Graves' thyrotoxicosis by sensitive bioassay for thyroid-stimulating antibody measured in early pregnancy. TPOAb, TSAb
83  2016 Prevalence of Thyroid Nodules and Its Relationship with Iodine Status in Shanghai: a Population-based Study. TgAb, TNs, TPOAb, TSH, UICs
84  2016 The Effect of Early Thyroidectomy on the Course of Active Graves' Orbitopathy (GO): A Retrospective Case Study. ATD, GO
85  2016 The Natural History of Subclinical Hyperthyroidism in Graves' Disease: The Rule of Thirds. CI, GD, SH
86  2015 A 2013 European survey of clinical practice patterns in the management of Graves' disease. ATD, ETA, GD, RAI
87  2015 Moyamoya disease concurrent with Graves' disease treated by direct bypass: clinical features and treatment strategies. GD, MMD, mRS, STA-MCA, TSH
88  2015 Onset of Graves' disease during long-term immunosuppressive therapy in a patient with membranous nephropathy. AITD, CyA
89  2015 Organ specificity in autoimmune diseases: thyroid and islet autoimmunity in alopecia areata. AA, Pc
90  2015 Outcome Prediction of Treatment of Graves' Hyperthyroidism with Antithyroid Drugs. ATDs
91  2015 Triiodothyronine-predominant Graves' disease in childhood: detection and therapeutic implications. ATD, FT3
92  2015 TSH receptor antibody titers measured with a third-generation assay did not reflect the activity of Graves' ophthalmopathy in untreated Japanese Graves' disease patients. CAS, GO, MRI, SEOMA, STIR
93  2014 A Case of Marine-Lenhart Syndrome with a Negative TSH Receptor Antibody Titer Successfully Treated with a Fixed, Low Dose of I (131.). ---
94  2014 Increased TRAb and/or low anti-TPO titers at diagnosis of graves' disease are associated with an increased risk of developing ophthalmopathy after onset. GD, GO
95  2014 Pregnancy after definitive treatment for Graves' disease--does treatment choice influence outcome? ---
96  2014 Preoperative subclinical hyperthyroidism in patients with papillary thyroid carcinoma. ETE, PTC, TSH
97  2014 Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves' orbitopathy: A five-year follow-up study. CAS, GO, RTX
98  2014 Risk factors for neonatal thyroid dysfunction in pregnancies complicated by Graves' disease. TSH
99  2014 Severe fetal and neonatal hyperthyroidism years after surgical treatment of maternal Graves' disease. ATD, GA
100  2014 Thymic hyperplasia in patients with Graves' disease. GD, TH